NSCLC, Stage I Clinical Trial
Official title:
Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery: Exploring Safety and Immunological Proof of Principle.
This study aims to evaluate the safety and mechanisms of action of the trimodality treatment (radiotherapy, immunotherapy and surgery) in early-stage non-small cell lung cancer. Half of the patients will receive stereotactic ablative radiotherapy followed by 2 cycles of immunotherapy (pembrolizumab); the other half will not receive the immunotherapy treatment. After treatment, both groups will continue treatment according to guidelines and will undergo surgery (lobectomy).
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | May 2020 |
Est. primary completion date | May 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Have a histologically or cytologically confirmed diagnosis of early stage (T1bN0 and T2aN0) peripherally located NCSLC, eligible for surgical resection. 2. Be willing and able to provide written informed consent/assent for the trial. 3. Be 18 years of age or over on day of signing informed consent. 4. Have measurable disease based on RECIST 1.1. 5. Must provide tissue from a core or excisional biopsy of the primary tumor lesion. 6. Have a performance status of 0-1 on the ECOG Performance Scale. 7. Demonstrate adequate organ function, all screening labs should be performed within 10 days of treatment initiation. 8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 9. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. 10. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy. Exclusion Criteria: - 1. Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment. 2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. 3. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. 4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. 5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. 6. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study. 7. Has a history of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis. 8. Has an active infection requiring systemic therapy. 9. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 10. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 11. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. 12. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). 13. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). 14. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). 15. Has received a live vaccine within 30 days prior to the first dose of trial treatment. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
VU University Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and severity of adverse events in patients treated by combining SBRT and pembrolizumab | Safety of the combination of SBRT and pembrolizumab will be assessed by the percentage of =3 pneumonitis. When combined SBRT and pembrolizumab treatment results in NCIC-CTC grade =3 pneumonitis in =10% of patients, the combination is regarded as safe. Serious adverse events will be recorded to assess both incidence and severity. | Up to 90 days post-treatment | |
Secondary | PD-1 expression | PD-1 expression in tumor tissue, tumordraining lymphnodes and peripheral blood. | Up to 90 days post-treatment | |
Secondary | PD-L1 expression | PD-L1 expression in tumor tissue, tumordraining lymphnodes and peripheral blood. | Up to 90 days post-treatment | |
Secondary | CD4 expression | CD4 expression in tumor tissue, tumordraining lymphnodes and peripheral blood. | Up to 90 days post-treatment | |
Secondary | CD8 expression | CD8 expression in tumor tissue, TDLN's and peripheral blood. | Up to 90 days post-treatment | |
Secondary | FoxP3 expression | FoxP3 expression in tumor tissue, tumordraining lymphnodes and peripheral blood. | Up to 90 days post-treatment | |
Secondary | Ki67 expression | Ki67 expression in tumor tissue, tumordraining lymphnodes and peripheral blood. | Up to 90 days post-treatment | |
Secondary | Immune cell count | Cell count of the individual immune cells in tumordraining lymphnodes and non-tumordraining lymphnodes | Up to 90 days post-treatment | |
Secondary | Analysis of PET data - SUVmax (standardized uptake value) | SUVmax will be measured in all tumor lesions, enlarged lymph nodes and liver, kidneys, lungs, spleen and left ventricle of the heart. | Up to 90 days post-treatment | |
Secondary | Analysis of PET data - SUVpeak (standardized uptake value) | SUVpeak will be measured in all tumor lesions, enlarged lymph nodes and liver, kidneys, lungs, spleen and left ventricle of the heart. | Up to 90 days post-treatment | |
Secondary | Analysis of PET data -SUVmean (standardized uptake value) | SUVmean will be measured in all tumor lesions, enlarged lymph nodes and liver, kidneys, lungs, spleen and left ventricle of the heart. | Up to 90 days post-treatment | |
Secondary | Analysis of CT data - Hounsfield Unit density | The pre- and post SBRT +/- pembrolizumab CT scans will be assessed for HU density and f-air values | Up to 90 days post-treatment | |
Secondary | Analysis of CT data - f-air values | The pre- and post SBRT +/- pembrolizumab CT scans will be assessed for and f-air values | Up to 90 days post-treatment | |
Secondary | Correlation between PET data and Blood + Tissue markers | The data of the PET-scan will be analyzed and compared to the blood and tissue samples to find a correlation between findings. | Up to 90 days post-treatment | |
Secondary | Correlation between tumor uptake of Zr89-pembrolizumab and irAEs | SUV are values used to describe PET-data. irAE's are specific adverse events. This outcome aims to correlate the (possible) irAE's with the PET-data. | Up to 90 days post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05686434 -
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
|
Phase 2 | |
Recruiting |
NCT04317534 -
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
|
Phase 2 | |
Recruiting |
NCT04205552 -
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
|
Phase 2 | |
Not yet recruiting |
NCT06467383 -
A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
|
||
Recruiting |
NCT04830826 -
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
|
||
Recruiting |
NCT06404164 -
Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
|
N/A | |
Recruiting |
NCT03454685 -
The Role of Microbiota on the Development of Lung Cancer
|
||
Enrolling by invitation |
NCT06028412 -
Comparison of Segmentectomy and Lobectomy in Small (2 cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study
|
N/A | |
Recruiting |
NCT03446547 -
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
|
Phase 2 |